Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Correction to: KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.

Hewitt LC, Saito Y, Wang T, Matsuda Y, Oosting J, Silva ANS, Slaney HL, Melotte V, Hutchins G, Tan P, Yoshikawa T, Arai T, Grabsch HI.

Gastric Cancer. 2019 Jun 6. doi: 10.1007/s10120-019-00975-3. [Epub ahead of print]

PMID:
31172308
2.

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.

Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, Oosting J, Singh N, Smit HCSH, Smit VTHBM, Van de Vijver KK, Bosse T.

Histopathology. 2019 Jul;75(1):128-136. doi: 10.1111/his.13871. Epub 2019 Jun 10.

PMID:
31155736
3.

KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.

Hewitt LC, Saito Y, Wang T, Matsuda Y, Oosting J, Silva ANS, Slaney HL, Melotte V, Hutchins G, Tan P, Yoshikawa T, Arai T, Grabsch HI.

Gastric Cancer. 2019 May 20. doi: 10.1007/s10120-019-00972-6. [Epub ahead of print] Erratum in: Gastric Cancer. 2019 Jun 6;:.

PMID:
31111275
4.

Allelic Switching of DLX5, GRB10, and SVOPL during Colorectal Cancer Tumorigenesis.

Boot A, Oosting J, Doorn S, Ouahoud S, Ventayol Garcia M, Ruano D, Morreau H, van Wezel T.

Int J Genomics. 2019 Apr 10;2019:1287671. doi: 10.1155/2019/1287671. eCollection 2019.

5.

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.

Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H.

Oncotarget. 2019 Mar 22;10(24):2416. doi: 10.18632/oncotarget.26820. eCollection 2019 Mar 22.

6.

Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.

Sandberg TP, Stuart MPME, Oosting J, Tollenaar RAEM, Sier CFM, Mesker WE.

BMC Cancer. 2019 Mar 29;19(1):284. doi: 10.1186/s12885-019-5462-2.

7.

Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.

Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H.

Oncotarget. 2018 Jul 31;9(59):31502-31515. doi: 10.18632/oncotarget.25845. eCollection 2018 Jul 31. Erratum in: Oncotarget. 2019 Mar 22;10(24):2416.

8.

For Debate: Personalized Health Care: As Exemplified by Home Sodium Measurements in a Child with Central Diabetes Insipidus and Impaired Thirst Perception.

van der Linde AAA, van Herwaarden AE, Oosting JD, Claahsen-van der Grinten HL, de Grouw EPLM.

Pediatr Endocrinol Rev. 2018 Apr;15(4):276-279. doi: 10.17458/per.vol15.2018.lho.fd.CentralDiabetesInsipidus.

PMID:
29806747
9.

Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Schubert SA, Ruano D, Elsayed FA, Boot A, Crobach S, Sarasqueta AF, Wolffenbuttel B, van der Klauw MM, Oosting J, Tops CM, van Eijk R, Vasen HF, Vossen RH, Nielsen M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, Morreau H, de Miranda NF, Sijmons RH, van Wezel T.

Br J Cancer. 2018 Jan;118(2):e4. doi: 10.1038/bjc.2017.380. Epub 2017 Oct 12. No abstract available.

10.

ROS-induced near-homozygous genomes in thyroid cancer.

Corver WE, Demmers J, Oosting J, Sahraeian S, Boot A, Ruano D, Wezel TV, Morreau H.

Endocr Relat Cancer. 2018 Jan;25(1):83-97. doi: 10.1530/ERC-17-0288. Epub 2017 Oct 24.

PMID:
29066502
11.

Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.

Boot A, Oosting J, van Eendenburg JDH, Kuppen PJK, Morreau H, van Wezel T.

PLoS One. 2017 Sep 20;12(9):e0184900. doi: 10.1371/journal.pone.0184900. eCollection 2017.

12.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

13.

Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Schubert SA, Ruano D, Elsayed FA, Boot A, Crobach S, Sarasqueta AF, Wolffenbuttel B, van der Klauw MM, Oosting J, Tops CM, van Eijk R, Vasen HF, Vossen RH, Nielsen M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, Morreau H, de Miranda NF, Sijmons RH, van Wezel T.

Br J Cancer. 2017 Sep 5;117(6):1215-1223. doi: 10.1038/bjc.2017.240. Epub 2017 Jul 25. Erratum in: Br J Cancer. 2018 Jan;118(2):e4.

14.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

15.

Clinical evaluation of Statstrip® Lactate for use in fetal scalp blood sampling.

Heinis A, van Dillen J, Oosting J, Rhöse S, Vandenbussche F, Van Drongelen J.

Acta Obstet Gynecol Scand. 2017 Mar;96(3):334-341. doi: 10.1111/aogs.13078. Epub 2017 Feb 3.

PMID:
27935627
16.

Imprinted survival genes preclude loss of heterozygosity of chromosome 7 in cancer cells.

Boot A, Oosting J, de Miranda NF, Zhang Y, Corver WE, van de Water B, Morreau H, van Wezel T.

J Pathol. 2016 Sep;240(1):72-83. doi: 10.1002/path.4756.

PMID:
27265324
17.

Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples.

Rotteveel-de Groot DM, Ross HA, Janssen MJR, Netea-Maier RT, Oosting JD, Sweep FCGJ, van Herwaarden AE.

Pract Lab Med. 2016 Mar 3;5:6-13. doi: 10.1016/j.plabm.2016.02.001. eCollection 2016 Aug 1.

18.

Characterization of novel low passage primary and metastatic colorectal cancer cell lines.

Boot A, van Eendenburg J, Crobach S, Ruano D, Speetjens F, Calame J, Oosting J, Morreau H, van Wezel T.

Oncotarget. 2016 Mar 22;7(12):14499-509. doi: 10.18632/oncotarget.7391.

19.

Copy number alterations and allelic ratio in relation to recurrence of rectal cancer.

Goossens-Beumer IJ, Oosting J, Corver WE, Janssen MJ, Janssen B, van Workum W, Zeestraten EC, van de Velde CJ, Morreau H, Kuppen PJ, van Wezel T.

BMC Genomics. 2015 Jun 6;16:438. doi: 10.1186/s12864-015-1550-0.

20.

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.

Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, Riester SM, Dudakovic A, Danen E, Cleton-Jansen AM, van Wijnen AJ, Bovée JV.

Oncotarget. 2015 May 20;6(14):12505-19.

21.

Near-haploidization significantly associates with oncocytic adrenocortical, thyroid, and parathyroid tumors but not with mitochondrial DNA mutations.

Corver WE, van Wezel T, Molenaar K, Schrumpf M, van den Akker B, van Eijk R, Ruano Neto D, Oosting J, Morreau H.

Genes Chromosomes Cancer. 2014 Oct;53(10):833-44. doi: 10.1002/gcc.22194. Epub 2014 Jun 7.

PMID:
24909752
22.

Hematologic parameters predicting a response to oral iron therapy in chronic inflammation.

van Santen S, de Mast Q, Oosting JD, van Ede A, Swinkels DW, van der Ven AJ.

Haematologica. 2014 Sep;99(9):e171-3. doi: 10.3324/haematol.2014.106799. Epub 2014 Jun 3. No abstract available.

23.

Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer.

van den Tillaart SA, Corver WE, Ruano Neto D, ter Haar NT, Goeman JJ, Trimbos JB, Fleuren GJ, Oosting J.

PLoS One. 2013 Jul 9;8(7):e67414. doi: 10.1371/journal.pone.0067414. Print 2013.

24.

Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer.

Sarasqueta AF, Forte G, Corver WE, de Miranda NF, Ruano D, van Eijk R, Oosting J, Tollenaar RA, van Wezel T, Morreau H.

BMC Cancer. 2013 Jun 5;13:277. doi: 10.1186/1471-2407-13-277.

25.

Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.

Verbeke SL, Bertoni F, Bacchini P, Oosting J, Sciot R, Krenács T, Bovée JV.

Mod Pathol. 2013 Sep;26(9):1211-21. doi: 10.1038/modpathol.2013.56. Epub 2013 Apr 19.

26.

Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.

van Oosterwijk JG, Meijer D, van Ruler MA, van den Akker BE, Oosting J, Krenács T, Picci P, Flanagan AM, Liegl-Atzwanger B, Leithner A, Athanasou N, Daugaard S, Hogendoorn PC, Bovée JV.

Am J Pathol. 2013 Apr;182(4):1347-56. doi: 10.1016/j.ajpath.2012.12.036. Epub 2013 Feb 15.

PMID:
23415961
27.

Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma.

Corver WE, Ruano D, Weijers K, den Hartog WC, van Nieuwenhuizen MP, de Miranda N, van Eijk R, Middeldorp A, Jordanova ES, Oosting J, Kapiteijn E, Hovens G, Smit J, van Wezel T, Morreau H.

PLoS One. 2012;7(6):e38287. doi: 10.1371/journal.pone.0038287. Epub 2012 Jun 1.

28.

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.

Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JV.

Nat Genet. 2011 Nov 6;43(12):1256-61. doi: 10.1038/ng.1004.

29.

Cervical carcinoma-associated fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations.

Corver WE, Ter Haar NT, Fleuren GJ, Oosting J.

Cell Oncol (Dordr). 2011 Dec;34(6):553-63. doi: 10.1007/s13402-011-0061-5. Epub 2011 Nov 1.

30.

Maffucci syndrome: a genome-wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases.

Pansuriya TC, Oosting J, Verdegaal SH, Flanagan AM, Sciot R, Kindblom LG, Hogendoorn PC, Szuhai K, Bovée JV.

Genes Chromosomes Cancer. 2011 Sep;50(9):673-9. doi: 10.1002/gcc.20889. Epub 2011 May 16.

PMID:
21584901
31.

Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas.

Middeldorp A, van Eijk R, Oosting J, Forte GI, van Puijenbroek M, van Nieuwenhuizen M, Corver WE, Ruano D, Caldes T, Wijnen J, Morreau H, van Wezel T.

Int J Cancer. 2012 Feb 15;130(4):837-46. doi: 10.1002/ijc.26093. Epub 2011 Jul 15.

32.

Genome-wide analysis of Ollier disease: Is it all in the genes?

Pansuriya TC, Oosting J, Krenács T, Taminiau AH, Verdegaal SH, Sangiorgi L, Sciot R, Hogendoorn PC, Szuhai K, Bovée JV.

Orphanet J Rare Dis. 2011 Jan 14;6:2. doi: 10.1186/1750-1172-6-2.

33.

Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?

van Roon EH, van Puijenbroek M, Middeldorp A, van Eijk R, de Meijer EJ, Erasmus D, Wouters KA, van Engeland M, Oosting J, Hes FJ, Tops CM, van Wezel T, Boer JM, Morreau H.

BMC Cancer. 2010 May 5;10:180. doi: 10.1186/1471-2407-10-180.

34.

MLPAinter for MLPA interpretation: an integrated approach for the analysis, visualisation and data management of Multiplex Ligation-dependent Probe Amplification.

van Eijk R, Eilers PH, Natté R, Cleton-Jansen AM, Morreau H, van Wezel T, Oosting J.

BMC Bioinformatics. 2010 Jan 29;11:67. doi: 10.1186/1471-2105-11-67.

35.

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.

Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PC.

Br J Cancer. 2009 Dec 15;101(12):2064. doi: 10.1038/sj.bjc.6605482. No abstract available.

36.

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.

Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PC.

Br J Cancer. 2009 Dec 1;101(11):1909-18. doi: 10.1038/sj.bjc.6605405. Epub 2009 Nov 3. Erratum in: Br J Cancer. 2009 Dec 15;101(12):2064.

37.

Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.

Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Clin Cancer Res. 2009 Jun 15;15(12):4191-8. doi: 10.1158/1078-0432.CCR-08-3297. Epub 2009 Jun 9.

38.

Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis.

Hensen EF, Goeman JJ, Oosting J, Van der Mey AG, Hogendoorn PC, Cremers CW, Devilee P, Cornelisse CJ.

BMC Med Genomics. 2009 May 11;2:25. doi: 10.1186/1755-8794-2-25.

39.

Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations.

Corver WE, Middeldorp A, ter Haar NT, Jordanova ES, van Puijenbroek M, van Eijk R, Cornelisse CJ, Fleuren GJ, Morreau H, Oosting J, van Wezel T.

Cancer Res. 2008 Dec 15;68(24):10333-40. doi: 10.1158/0008-5472.CAN-08-2665.

40.

E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.

De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W, van Engeland M, Sieben NL.

J Pathol. 2009 Jan;217(1):14-20. doi: 10.1002/path.2452.

PMID:
18991331
41.

Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis.

Lips EH, van Eijk R, de Graaf EJ, Oosting J, de Miranda NF, Karsten T, van de Velde CJ, Eilers PH, Tollenaar RA, van Wezel T, Morreau H.

BMC Cancer. 2008 Oct 29;8:314. doi: 10.1186/1471-2407-8-314.

42.

Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: a pathway-based analysis.

Hensen EF, De Herdt MJ, Goeman JJ, Oosting J, Smit VT, Cornelisse CJ, Baatenburg de Jong RJ.

BMC Cancer. 2008 Jun 10;8:168. doi: 10.1186/1471-2407-8-168.

43.

High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomas.

Middeldorp A, van Puijenbroek M, Nielsen M, Corver WE, Jordanova ES, ter Haar N, Tops CM, Vasen HF, Lips EH, van Eijk R, Hes FJ, Oosting J, Wijnen J, van Wezel T, Morreau H.

J Pathol. 2008 Sep;216(1):25-31. doi: 10.1002/path.2375.

PMID:
18506705
44.

Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma.

Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, ter Haar N, Dreef EJ, Kenter GG, Jordanova ES.

J Pathol. 2008 Jul;215(3):222-30. doi: 10.1002/path.2347.

PMID:
18438953
45.

Genome-wide copy neutral LOH is infrequent in familial and sporadic microsatellite unstable carcinomas.

van Puijenbroek M, Middeldorp A, Tops CM, van Eijk R, van der Klift HM, Vasen HF, Wijnen JT, Hes FJ, Oosting J, van Wezel T, Morreau H.

Fam Cancer. 2008;7(4):319-30. doi: 10.1007/s10689-008-9194-8. Epub 2008 Apr 15.

PMID:
18415027
46.

Progression and tumor heterogeneity analysis in early rectal cancer.

Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, Karsten T, Eilers PH, Tollenaar RA, van Wezel T, Morreau H.

Clin Cancer Res. 2008 Feb 1;14(3):772-81. doi: 10.1158/1078-0432.CCR-07-2052.

47.

Ondansetron and pruritus in chronic liver disease: a controlled study.

Jones EA, Molenaar HA, Oosting J.

Hepatogastroenterology. 2007 Jun;54(76):1196-9.

PMID:
17629069
48.

The role of noncartilage-specific molecules in differentiation of cartilaginous tumors: lessons from chondroblastoma and chondromyxoid fibroma.

Romeo S, Oosting J, Rozeman LB, Hameetman L, Taminiau AH, Cleton-Jansen AM, Bovée JV, Hogendoorn PC.

Cancer. 2007 Jul 15;110(2):385-94.

49.

Single nucleotide polymorphism array analysis of chromosomal instability patterns discriminates rectal adenomas from carcinomas.

Lips EH, de Graaf EJ, Tollenaar RA, van Eijk R, Oosting J, Szuhai K, Karsten T, Nanya Y, Ogawa S, van de Velde CJ, Eilers PH, van Wezel T, Morreau H.

J Pathol. 2007 Jul;212(3):269-77.

PMID:
17471469
50.

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

Kloth JN, Oosting J, van Wezel T, Szuhai K, Knijnenburg J, Gorter A, Kenter GG, Fleuren GJ, Jordanova ES.

BMC Genomics. 2007 Feb 20;8:53.

Supplemental Content

Loading ...
Support Center